Prognostic Value of Epidermal Growth Factor Receptor in Patients with Glioblastoma Multiforme

Naoki Shinojima, Kenji Tada, Shoji Shiraishi, Takanori Kamiryo, Masato Kochi, Hideo Nakamura, Keishi Makino, Hideyuki Saya, Hirofumi Hirano, Jun Ichi Kuratsu, Koji Oka, Yasuji Ishimaru, Yukitaka Ushio

Research output: Contribution to journalArticle

480 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) frequently involves amplification and alteration of the epidermal growth factor receptor (EGFR) gene, resulting in overexpression of varied mutations, including the most common mutation, EGFRvIII, as well as wild-type EGFR (EGFRwt). To test the prognostic value of EGFR, we retrospectively analyzed the relationship between treatment outcomes and the EGFR gene in 87 newly diagnosed adult patients with supratentorial GBM enrolled in clinical trials. The EGFR gene status was assessed by Southern blots and EGFR expression by immunohistochemistry using three monoclonal antibodies (EGFR.25 for EGFR, EGFR.113 for EGFRwt, and DH8.3 for EGFRvIII). EGFR amplification was detected in 40 (46%) of the 87 GBM patients; in 39 (97.5%) of these, EGFR was overexpressed. On the other hand, in 46 of 47 patients without EGFR amplification (97.9%), no EGFR overexpression was present. There was a close correlation between EGFR amplification and EGFR overexpression (P < 0.0001). EGFRwt was overexpressed in 27 of the 40 (67.5%) patients with, and in none without, EGFR amplification (P < 0.0001). Similarly, EGFRvIII was overexpressed in 18 (45.0%) of 40 patients with and in 4 (8.5%) of 47 patients without EGFR amplification (P < 0.0001). The finding that 8 (20%) of the patients with EGFR amplification/EGFR overexpression manifested overexpression of neither EGFRwt nor EGFRvIII indicates that they overexpressed other types of EGFR. Multivariate analysis demonstrated that EGFR amplification was an independent, significant, unfavorable predictor for overall survival (OS) in all patients (P = 0.038, HR = 1.67). With respect to the relationship of age to EGFR prognostication, the EGFR gene status was a more significant prognosticator in younger patients, particularly in those <60 years (P = 0.0003, HR = 3.15), whereas not so in older patients. EGFRvIII overexpression, on the other hand, was not predictive for OS. However, in patients with EGFR amplification, multivariate analysis revealed that EGFRvIII overexpression was an independent, significant, poor prognostic factor for OS (P = 0.0044, HR = 2.71). This finding indicates that EGFRvIII overexpression in the presence of EGFR amplification is the strongest indicator of a poor survival prognosis. In GBM patients, EGFR is of significant prognostic value for predicting survival, and the overexpression of EGFRvIII with amplification plays an important role in enhanced tumorigenicity.

Original languageEnglish
Pages (from-to)6962-6970
Number of pages9
JournalCancer Research
Volume63
Issue number20
Publication statusPublished - 2003 Oct 15
Externally publishedYes

Fingerprint

Glioblastoma
Epidermal Growth Factor Receptor
erbB-1 Genes
Survival
Multivariate Analysis
Mutation
epidermal growth factor receptor VIII

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., ... Ushio, Y. (2003). Prognostic Value of Epidermal Growth Factor Receptor in Patients with Glioblastoma Multiforme. Cancer Research, 63(20), 6962-6970.

Prognostic Value of Epidermal Growth Factor Receptor in Patients with Glioblastoma Multiforme. / Shinojima, Naoki; Tada, Kenji; Shiraishi, Shoji; Kamiryo, Takanori; Kochi, Masato; Nakamura, Hideo; Makino, Keishi; Saya, Hideyuki; Hirano, Hirofumi; Kuratsu, Jun Ichi; Oka, Koji; Ishimaru, Yasuji; Ushio, Yukitaka.

In: Cancer Research, Vol. 63, No. 20, 15.10.2003, p. 6962-6970.

Research output: Contribution to journalArticle

Shinojima, N, Tada, K, Shiraishi, S, Kamiryo, T, Kochi, M, Nakamura, H, Makino, K, Saya, H, Hirano, H, Kuratsu, JI, Oka, K, Ishimaru, Y & Ushio, Y 2003, 'Prognostic Value of Epidermal Growth Factor Receptor in Patients with Glioblastoma Multiforme', Cancer Research, vol. 63, no. 20, pp. 6962-6970.
Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H et al. Prognostic Value of Epidermal Growth Factor Receptor in Patients with Glioblastoma Multiforme. Cancer Research. 2003 Oct 15;63(20):6962-6970.
Shinojima, Naoki ; Tada, Kenji ; Shiraishi, Shoji ; Kamiryo, Takanori ; Kochi, Masato ; Nakamura, Hideo ; Makino, Keishi ; Saya, Hideyuki ; Hirano, Hirofumi ; Kuratsu, Jun Ichi ; Oka, Koji ; Ishimaru, Yasuji ; Ushio, Yukitaka. / Prognostic Value of Epidermal Growth Factor Receptor in Patients with Glioblastoma Multiforme. In: Cancer Research. 2003 ; Vol. 63, No. 20. pp. 6962-6970.
@article{8eb746a7e1e64dfead23bf1bcab432c9,
title = "Prognostic Value of Epidermal Growth Factor Receptor in Patients with Glioblastoma Multiforme",
abstract = "Glioblastoma multiforme (GBM) frequently involves amplification and alteration of the epidermal growth factor receptor (EGFR) gene, resulting in overexpression of varied mutations, including the most common mutation, EGFRvIII, as well as wild-type EGFR (EGFRwt). To test the prognostic value of EGFR, we retrospectively analyzed the relationship between treatment outcomes and the EGFR gene in 87 newly diagnosed adult patients with supratentorial GBM enrolled in clinical trials. The EGFR gene status was assessed by Southern blots and EGFR expression by immunohistochemistry using three monoclonal antibodies (EGFR.25 for EGFR, EGFR.113 for EGFRwt, and DH8.3 for EGFRvIII). EGFR amplification was detected in 40 (46{\%}) of the 87 GBM patients; in 39 (97.5{\%}) of these, EGFR was overexpressed. On the other hand, in 46 of 47 patients without EGFR amplification (97.9{\%}), no EGFR overexpression was present. There was a close correlation between EGFR amplification and EGFR overexpression (P < 0.0001). EGFRwt was overexpressed in 27 of the 40 (67.5{\%}) patients with, and in none without, EGFR amplification (P < 0.0001). Similarly, EGFRvIII was overexpressed in 18 (45.0{\%}) of 40 patients with and in 4 (8.5{\%}) of 47 patients without EGFR amplification (P < 0.0001). The finding that 8 (20{\%}) of the patients with EGFR amplification/EGFR overexpression manifested overexpression of neither EGFRwt nor EGFRvIII indicates that they overexpressed other types of EGFR. Multivariate analysis demonstrated that EGFR amplification was an independent, significant, unfavorable predictor for overall survival (OS) in all patients (P = 0.038, HR = 1.67). With respect to the relationship of age to EGFR prognostication, the EGFR gene status was a more significant prognosticator in younger patients, particularly in those <60 years (P = 0.0003, HR = 3.15), whereas not so in older patients. EGFRvIII overexpression, on the other hand, was not predictive for OS. However, in patients with EGFR amplification, multivariate analysis revealed that EGFRvIII overexpression was an independent, significant, poor prognostic factor for OS (P = 0.0044, HR = 2.71). This finding indicates that EGFRvIII overexpression in the presence of EGFR amplification is the strongest indicator of a poor survival prognosis. In GBM patients, EGFR is of significant prognostic value for predicting survival, and the overexpression of EGFRvIII with amplification plays an important role in enhanced tumorigenicity.",
author = "Naoki Shinojima and Kenji Tada and Shoji Shiraishi and Takanori Kamiryo and Masato Kochi and Hideo Nakamura and Keishi Makino and Hideyuki Saya and Hirofumi Hirano and Kuratsu, {Jun Ichi} and Koji Oka and Yasuji Ishimaru and Yukitaka Ushio",
year = "2003",
month = "10",
day = "15",
language = "English",
volume = "63",
pages = "6962--6970",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Prognostic Value of Epidermal Growth Factor Receptor in Patients with Glioblastoma Multiforme

AU - Shinojima, Naoki

AU - Tada, Kenji

AU - Shiraishi, Shoji

AU - Kamiryo, Takanori

AU - Kochi, Masato

AU - Nakamura, Hideo

AU - Makino, Keishi

AU - Saya, Hideyuki

AU - Hirano, Hirofumi

AU - Kuratsu, Jun Ichi

AU - Oka, Koji

AU - Ishimaru, Yasuji

AU - Ushio, Yukitaka

PY - 2003/10/15

Y1 - 2003/10/15

N2 - Glioblastoma multiforme (GBM) frequently involves amplification and alteration of the epidermal growth factor receptor (EGFR) gene, resulting in overexpression of varied mutations, including the most common mutation, EGFRvIII, as well as wild-type EGFR (EGFRwt). To test the prognostic value of EGFR, we retrospectively analyzed the relationship between treatment outcomes and the EGFR gene in 87 newly diagnosed adult patients with supratentorial GBM enrolled in clinical trials. The EGFR gene status was assessed by Southern blots and EGFR expression by immunohistochemistry using three monoclonal antibodies (EGFR.25 for EGFR, EGFR.113 for EGFRwt, and DH8.3 for EGFRvIII). EGFR amplification was detected in 40 (46%) of the 87 GBM patients; in 39 (97.5%) of these, EGFR was overexpressed. On the other hand, in 46 of 47 patients without EGFR amplification (97.9%), no EGFR overexpression was present. There was a close correlation between EGFR amplification and EGFR overexpression (P < 0.0001). EGFRwt was overexpressed in 27 of the 40 (67.5%) patients with, and in none without, EGFR amplification (P < 0.0001). Similarly, EGFRvIII was overexpressed in 18 (45.0%) of 40 patients with and in 4 (8.5%) of 47 patients without EGFR amplification (P < 0.0001). The finding that 8 (20%) of the patients with EGFR amplification/EGFR overexpression manifested overexpression of neither EGFRwt nor EGFRvIII indicates that they overexpressed other types of EGFR. Multivariate analysis demonstrated that EGFR amplification was an independent, significant, unfavorable predictor for overall survival (OS) in all patients (P = 0.038, HR = 1.67). With respect to the relationship of age to EGFR prognostication, the EGFR gene status was a more significant prognosticator in younger patients, particularly in those <60 years (P = 0.0003, HR = 3.15), whereas not so in older patients. EGFRvIII overexpression, on the other hand, was not predictive for OS. However, in patients with EGFR amplification, multivariate analysis revealed that EGFRvIII overexpression was an independent, significant, poor prognostic factor for OS (P = 0.0044, HR = 2.71). This finding indicates that EGFRvIII overexpression in the presence of EGFR amplification is the strongest indicator of a poor survival prognosis. In GBM patients, EGFR is of significant prognostic value for predicting survival, and the overexpression of EGFRvIII with amplification plays an important role in enhanced tumorigenicity.

AB - Glioblastoma multiforme (GBM) frequently involves amplification and alteration of the epidermal growth factor receptor (EGFR) gene, resulting in overexpression of varied mutations, including the most common mutation, EGFRvIII, as well as wild-type EGFR (EGFRwt). To test the prognostic value of EGFR, we retrospectively analyzed the relationship between treatment outcomes and the EGFR gene in 87 newly diagnosed adult patients with supratentorial GBM enrolled in clinical trials. The EGFR gene status was assessed by Southern blots and EGFR expression by immunohistochemistry using three monoclonal antibodies (EGFR.25 for EGFR, EGFR.113 for EGFRwt, and DH8.3 for EGFRvIII). EGFR amplification was detected in 40 (46%) of the 87 GBM patients; in 39 (97.5%) of these, EGFR was overexpressed. On the other hand, in 46 of 47 patients without EGFR amplification (97.9%), no EGFR overexpression was present. There was a close correlation between EGFR amplification and EGFR overexpression (P < 0.0001). EGFRwt was overexpressed in 27 of the 40 (67.5%) patients with, and in none without, EGFR amplification (P < 0.0001). Similarly, EGFRvIII was overexpressed in 18 (45.0%) of 40 patients with and in 4 (8.5%) of 47 patients without EGFR amplification (P < 0.0001). The finding that 8 (20%) of the patients with EGFR amplification/EGFR overexpression manifested overexpression of neither EGFRwt nor EGFRvIII indicates that they overexpressed other types of EGFR. Multivariate analysis demonstrated that EGFR amplification was an independent, significant, unfavorable predictor for overall survival (OS) in all patients (P = 0.038, HR = 1.67). With respect to the relationship of age to EGFR prognostication, the EGFR gene status was a more significant prognosticator in younger patients, particularly in those <60 years (P = 0.0003, HR = 3.15), whereas not so in older patients. EGFRvIII overexpression, on the other hand, was not predictive for OS. However, in patients with EGFR amplification, multivariate analysis revealed that EGFRvIII overexpression was an independent, significant, poor prognostic factor for OS (P = 0.0044, HR = 2.71). This finding indicates that EGFRvIII overexpression in the presence of EGFR amplification is the strongest indicator of a poor survival prognosis. In GBM patients, EGFR is of significant prognostic value for predicting survival, and the overexpression of EGFRvIII with amplification plays an important role in enhanced tumorigenicity.

UR - http://www.scopus.com/inward/record.url?scp=0142188691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142188691&partnerID=8YFLogxK

M3 - Article

C2 - 14583498

AN - SCOPUS:0142188691

VL - 63

SP - 6962

EP - 6970

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 20

ER -